A Randomized, Open-Label, Comparative Study To Evaluate the Adhesion and Temperature Properties of Two Air-Activated, Adhesive Backed Heat Patches in Healthy Volunteers

Chattem, Inc.1 site in 1 country200 target enrollmentMarch 2014

ConditionsHealthy

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Healthy
Sponsor: Chattem, Inc.
Enrollment: 200
Locations: 1
Primary Endpoint: Heat Intensity
Status: Terminated
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

A disposable, air-activated, adhesive backed heat patch is being evaluated.

Study terminated -O subjects.

Detailed Description

Study Protocol Terminated--0 subjects

Registry

clinicaltrials.gov

Start Date

March 2014

End Date

May 2014

Last Updated

5 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Chattem, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subjects who complete an appropriately administered informed consent process that includes signing the IRB-approved consent form;
•subjects 18-75 years old of each sex;
•are of any skin type or race, providing the skin pigmentation will allow discernment of erythema;
•subjects who are in good general health and free of any disease state or physical condition;
•subjects who are willing and able to have the study products applied as directed, and comply with study instructions;
•subjects must be willing to restrict their activity for the 8 hour patch wear time so that patches and thermocouples do not come loose;
•subjects must be willing to wear a pouch containing the thermologger and thermocouple wiring for the entire 8 hours;
•subjects who are 55 years or older agree to wear a t-shirt provided by the site for the entire 8 hour patch wear time.

Exclusion Criteria

•Subjects who are pregnant or nursing;
•subjects with excessive hair at the application site, scar tissue, tattoo or coloration that would interfere with the placement of the study product or the skin assessment;
•subjects with diabetes or poor circulation or have any clinically significant chronic illness which could place the subject at increased risk during participation or result in inappropriate dermal response during the study;
•subjects unable to feel pain or heat (e.g., subjects with neuropathy);
•subjects with active dermatitis (including sunburn) in the treatment area or other visible dermatological disease which, in the investigator's opinion, might interfere with the response to the study products or interfere with the skin assessments associated with the study products;
•have history of significant dermatologic cancers or neoplasms in the treatment area;
•subjects who have used topical dermatological products in the application area within 24 hours prior to anticipated study product application;
•subjects using a concomitant medication that, in the investigator's opinion, could interfere with the interpretation of the study results. Examples of such drugs include vasoactive (constrictor or dilator) medications, prescription or OTC, that could modulate blood flow, within 24 hours prior to or during the application of study products, including nitroglycerin, non-steroidal anti-inflammatory products (NSAIDs, e.g., ibuprofen, aspirin (\<=81 mg/day is acceptable)), topical corticosteroids and OTC cough/cold products including antihistamines and/or either phenylpropanolamine or phentolamine;
•subjects who have used systemic steroids (i.e., oral, IV, IM or intra-articular) 30 days prior to the application of test articles (intranasal/inhaled steroids are acceptable);
•subjects who have received an investigational medication or device within 30 days prior to enrollment into this study;